Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer.
about
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemopreventionLipid-sensors, enigmatic-orphan and orphan nuclear receptors as therapeutic targets in breast-cancerStructural Basis for Activation of Fatty Acid-binding Protein 4The non-genomic crosstalk between PPAR-gamma ligands and ERK1/2 in cancer cell linesIndirect genomic effects on survival from gene expression dataResearch resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancerCannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.Cardiac remodeling in obesity.The impact of type 2 diabetes and antidiabetic drugs on cancer cell growthObesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFbeta signalling.Expression of peroxisome proliferator activated receptor gamma and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma.Modification of MCF-10A cells with pioglitazone and serum-rich growth medium increases soluble factors in the conditioned medium, likely reducing BT-474 cell growth.Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells.PPARs in alveolar macrophage biology.PPARγ agonists target aromatase via both PGE2 and BRCA1.Modulation of PPAR-γ by Nutraceutics as Complementary Treatment for Obesity-Related Disorders and Inflammatory DiseasesThe transcriptional co-factor RIP140 regulates mammary gland development by promoting the generation of key mitogenic signalsPPARgamma and PPARdelta as Modulators of Neoplasia and Cell FatePPARgamma and MEK Interactions in CancerPPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.Cucurbitane Triterpenoid from Momordica charantia Induces Apoptosis and Autophagy in Breast Cancer Cells, in Part, through Peroxisome Proliferator-Activated Receptor γ Activation.Enhanced angiogenesis in obesity and in response to PPARgamma activators through adipocyte VEGF and ANGPTL4 production.Thiazolidinediones as anti-cancer agents.MicroRNA expression and gene regulation drive breast cancer progression and metastasis in PyMT mice.Human adipose-derived stem cell adipogenesis induces paracrine regulation of the invasive ability of MCF-7 human breast cancer cells in vitro.Macrophage PPARγ inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone.Mixed tocopherols prevent mammary tumorigenesis by inhibiting estrogen action and activating PPAR-gamma.A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia.Ligand-activated PPARγ downregulates CXCR4 gene expression through a novel identified PPAR response element and inhibits breast cancer progression.Effects of conjugated linoleic acid on cleavage of amyloid precursor protein via PPARγ.Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines.Ligands of the peroxisome proliferator-activated receptor γ inhibit hepatoce llular carcinoma cell proliferation.PPARgamma and Agonists against Cancer: Rational Design of Complementation Treatments.PPARγ and PPARGC1B polymorphisms modify the association between phthalate metabolites and breast cancer risk.Troglitazone Inhibits Matrix Metalloproteinase-9 Expression and Invasion of Breast Cancer Cell through a Peroxisome Proliferator-Activated Receptor γ-Dependent Mechanism.LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state
P2860
Q24601222-7FF09C8B-8F16-4E98-A315-B39C5B5D0E6FQ26764743-6EA3E66C-3EEA-42E7-87D6-88426428AC5EQ27647673-5E9C972E-4C84-4975-A6AC-7222305A3684Q28238709-96C06B95-C82D-4FED-92F0-E6B349D9B909Q31150308-553A4359-4414-48EE-8D0C-157903A1AC76Q33637070-91846538-5F91-4988-B507-F5DB52D9E0B1Q33845285-167F4D57-BA21-42BD-8ED9-E497CDE0CC2EQ34043589-32069C0E-EF01-48DF-B121-13918FA2266DQ34095570-336D6F23-ED18-4D5B-926A-D769F8EA4501Q34996841-E4ECCB68-D07D-4E74-B1A9-7FE50B13A252Q35458969-0AB91786-1161-45F0-905F-50E3689D7356Q35770556-3070D8C1-B4B6-4AF1-BC14-B774FD6B74B1Q36057300-27CF314D-F945-4FBA-97A0-0443770C1818Q36059702-8C88F120-2A75-40E3-9323-C74CBA88E6E7Q36121727-D5F7BF99-6D70-48C0-A6F3-DCBB4419F177Q36303977-8F3F9004-EBD7-4580-8D89-46E08845FBB3Q36449677-05AFBBBC-31D9-4854-A7EE-C06E4ED6445BQ36640852-34F3C09E-42BB-444A-BBA5-5AC685B50162Q36724712-9FAB304C-AB58-42C3-95D7-6AE09ABDBD7BQ36737285-61ED87E5-53C7-417C-AA74-D1C76ED2576BQ36772391-47753573-D8BD-4865-A0A9-77DBEDBFF014Q36969586-091FFF9C-C561-45EC-AAC0-7F4A90C285D1Q36976999-AD7AB799-5B68-448A-B27A-CEC6B0E76F19Q37010188-DD5CAE20-DB76-4CDD-99A6-009686AEA2A9Q37119515-7142EEBE-C565-4D6D-8D5F-9B9B62B2DFB1Q37231266-C4A1FC3E-A318-46F9-A326-FD87F43A75CBQ37306048-E79640EF-5CC6-4100-93F9-124B56804355Q37366222-B7464A4D-7233-4B17-9D67-524E12141904Q37683288-62410D41-6158-46BB-99B9-98CBE20B4E81Q38828335-6D5CFB28-3975-49B0-A67D-F4F16C033AD1Q39498646-162180C8-839E-452D-A51D-7481CB67C0C1Q39650265-5998C9D8-DF46-4DA5-B669-B1BD1CD7EC54Q41298549-EBF6FAD1-1953-416A-A628-8631ADFBBE95Q41677812-E16CD301-B9C4-4111-B941-8174316BEA1FQ47985043-EAB182E4-7AD1-42E6-B7EC-5F63E1A02B76Q54092695-6C8EF84F-BE10-42E6-ADA0-05B390102734Q59136649-2A9DEAA4-DE54-4EBC-B9C0-CAD082E8AD9A
P2860
Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Peroxisome proliferator-activa ...... he treatment of breast cancer.
@ast
Peroxisome proliferator-activa ...... he treatment of breast cancer.
@en
type
label
Peroxisome proliferator-activa ...... he treatment of breast cancer.
@ast
Peroxisome proliferator-activa ...... he treatment of breast cancer.
@en
prefLabel
Peroxisome proliferator-activa ...... he treatment of breast cancer.
@ast
Peroxisome proliferator-activa ...... he treatment of breast cancer.
@en
P2860
P1476
Peroxisome proliferator-activa ...... he treatment of breast cancer.
@en
P2093
Elena Elstner
P2860
P304
P356
10.1517/13543784.14.6.557
P407
P577
2005-06-01T00:00:00Z